source
- Roivant's brepocitinib shows strong Phase 3 results, paving way for uveitis indicationRoivant subsidiary Priovant Therapeutics announced positive Phase 3 data for its anti‑inflammatory drug brepocitinib in patients with non‑infectious uveitis, an eye disease that can cause blindness…
- Crossover fundraisings may hit $4.2 billion in 2026, with 2025 rounds still leading historic totalsCrossover rounds are viewed as a bridge to public markets, with Jim Healy of Sofinnova Investments saying a large raise signals a company has reached a level of maturity and broader institutional i…